Cambrex and AstraZeneca kick off manufacturing agreement

By Melissa Fassbender contact

- Last updated on GMT

Cambrex and AstraZeneca employees at the ceremony in Karlskoga, Sweden. (Image: Cambrex Corporation)
Cambrex and AstraZeneca employees at the ceremony in Karlskoga, Sweden. (Image: Cambrex Corporation)

Related tags: Finance, Capital accumulation

Cambrex and AstraZeneca have commenced a long-term manufacturing agreement with an opening ceremony at the CDMO’s site in Sweden.

The event marked the start of a long-term manufacturing agreement for a key intermediate, according to the contract development and manufacturing organization (CDMO).

The ceremony was held at Cambrex’s Karlskoga, Sweden site, at which the company recently increased capacity. As part of the expansion, which was announced in May 2017​, the company installed new multi-purpose reactors ranging from 4m3​ to 12m3​ in addition to a 9m3​ hydrogenation reactor.

The company also introduced additional continuous flow manufacturing for high purity intermediate production.

Shawn Cavanagh, COO of Cambrex, stated in a press release: “We have an excellent relationship with AstraZeneca dating back to the 1950s and are excited to partner with them on the long-term production of several important products.”

Cavanagh said the company will continue to invest in capabilities, technology and appropriate capacity at the Karlskoga site.

Since 2012, Cambrex has invested more than $200m in facility expansions, equipment, and upgrades to the company’s global sites.

Related topics: Contract Manufacturing & Logistics

Related news

Show more

Follow us

Products

View more

Webinars